Refine by
5,197 results found
-
Understanding the Necessity of Community First Response
This kind of first response directly improves safety and well-being by connecting people to appropriate care and resources. -
New NAMI Resource to Help Navigate Upcoming Changes in Medicaid for People with Mental Illness
NAMI has created a resource with tips for helping people ensure that they can have continued access to health insurance and mental health services during the Medicaid “unwinding period.” -
New NAMI Podcast Offers Insight and Inspiration on Mental Health Journeys
NAMI today launched “You Are Not Alone: Voices of Recovery,” an insightful podcast series based on the USA Today national bestseller “You Are Not Alone: The NAMI Guide to Navigating Mental Health,” by NAMI Chief Medical Officer Ken Duckworth, M.D. -
Thriving on the Bipolar Spectrum: Changing the Narrative with Stories of Lived Experience
We’re now on a shared mission to end the stigma, maximize healing and save lives by spreading education and inspiration. -
Statement on Health Coverage
Statement in response to the ruling in the Braidwood versus Becerra case, which threatens coverage of U.S. Preventive Services Task Force recommended preventive services without cost sharing as required under the Affordable Care Act. -
What It’s Like to Live with an OCD Monster
The people I trust look at my behaviors and see me — not the odd girl or the monster — a kaleidoscope of a human being. -
FDA Approves Over-the-Counter Naloxone Spray
Naloxone, commonly known under the brand name Narcan, is a medication that rapidly reverses the effects of an opioid overdose. Until this year, all forms of naloxone had been designated as prescription-only. After hearing from an expert advisory panel, the U.S. Food and Drug Administration (FDA) approved the sale of over-the-counter naloxone hydrocholoride nasal spray nationwide in March. The decision removes a critical access barrier to the life-saving treatment, thereby reducing overdose deaths and the associated stigma. Implementation will be ongoing in the coming months with pending information on the cost of the medication. To learn more, see the news release from the FDA. -
Lessons in Advocacy from a State and Federal Legislative Staffer
You should pursue policy change at every level of government and remember that slow and steady wins the race. -
Congressional Testimony on Mental Health Funding
Hannah Wesoloski’s Congressional testimony, on behalf of NAMI, to the House Labor-HHS-Education Appropriations Subcommittee on NAMI’s FY 2024 appropriations priorities.